EcoDrugPlus

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSSDUG00000017532
Gene Symbol: RELA
3 Cross references
199 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSDUG00000000302
Gene Symbol: RAF1
3 Cross references
207 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSSDUG00000016641
Gene Symbol: ROCK1
3 Cross references
213 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSSDUG00000018198
Gene Symbol: ROCK2
3 Cross references
225 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSSDUG00000005851
Gene Symbol: SEM1
1 Cross references
155 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSDUG00000017198
Gene Symbol: SRC
3 Cross references
192 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSSDUG00000015558
Gene Symbol: LOC111220510
3 Cross references
204 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSSDUG00000009332
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSSDUG00000002652
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSSDUG00000001626
Gene Symbol: WEE1
3 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSSDUG00000007935
Gene Symbol: YES1
4 Cross references
208 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSSDUG00000005641
Gene Symbol: ACHE
3 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).